WATERTOWN, Mass.--(BUSINESS WIRE)--Entact Bio, a company committed to improving the lives of patients by developing precision medicines that enhance the function of beneficial proteins, today announced the appointment of Ruben Tommasi, Ph.D., as Chief Scientific Officer. Dr. Tommasi joins Entact with three decades of experience in the life sciences industry, having held a series of leadership roles driving drug discovery across therapeutic areas at global pharmaceutical companies and innovative biotechs..

马萨诸塞州沃特敦（商业新闻短讯）--致力于通过开发增强有益蛋白质功能的精准药物来改善患者生活的Entact Bio公司今天宣布任命Ruben Tommasi博士为首席科学官。Tommasi博士加入Entact，在生命科学行业拥有三十年的经验，曾在全球制药公司和创新生物技术公司的治疗领域担任一系列领导角色，推动药物发现。。

“We’re thrilled to welcome Ruben, who brings deep expertise in drug discovery and has a proven record in successfully advancing compounds from program inception to clinical development and regulatory approval,” said Entact Bio CEO Victoria Richon, Ph.D. “His scientific leadership and experience in multiple therapeutic areas will progress our mission to expand the universe of treatable diseases for patients in need using an entirely new class of drugs.”.

Entact Bio首席执行官Victoria Richon博士说：“我们很高兴欢迎鲁本，他在药物发现方面拥有丰富的专业知识，并且在成功地将化合物从项目开始推进到临床开发和监管批准方面有着良好的记录。他在多个治疗领域的科学领导和经验将推动我们的使命，即为需要使用全新药物的患者扩大可治疗疾病的范围。”。

Dr. Tommasi joins Entact from Dunad Therapeutics where he served as Chief Scientific Officer and oversaw the discovery and development of the company’s next-generation targeted protein degradation therapies. Previously Dr. Tommasi served as Chief Scientific Officer for Entasis Therapeutics, where he led its drug discovery team and built a strong pipeline of antibacterial programs, including an asset that would go on to complete a successful Phase 3 study and another asset that later progressed to FDA approval..

Tommasi博士从Dunad Therapeutics加入Entact，担任首席科学官，并监督公司下一代靶向蛋白质降解疗法的发现和开发。此前，托马西博士担任Entasis Therapeutics的首席科学官，领导其药物发现团队，建立了强大的抗菌计划管道，包括一项将继续完成成功的3期研究的资产，以及另一项后来获得FDA批准的资产。。

Earlier in his career Dr. Tommasi held research leadership positions at AstraZeneca and the Novartis Institutes for Biomedical Research (NIBR) in infection, computational chemistry, and lead finding across metabolic diseases, oncology and ophthalmology. Dr. Tommasi received his BS in Chemistry summa cum laude followed by his Ph.D.

在职业生涯早期，托马西博士曾在阿斯利康和诺华生物医学研究所（NIBR）担任感染，计算化学方面的研究领导职务，并在代谢疾病，肿瘤学和眼科领域取得领先发现。托马西博士以优异成绩获得了化学学士学位，随后获得了博士学位。

in Organic Chemistry at the State University of New York at Albany. He completed post-doctoral fellowships at the University of Colorado at Boulder and The Upjohn Company..

奥尔巴尼纽约州立大学有机化学专业。他在科罗拉多大学博尔德分校和Upjohn公司获得博士后奖学金。。

“I was very attracted to the innovative modality Entact is developing as it holds tremendous potential to pursue new, undrugged targets believed to be beneficial against disease,” said Dr. Tommasi. “The progress the company has made developing the Encompass™ platform is impressive, and I’m excited about leading the scientific efforts and sharing in the team’s passion for introducing new therapeutic options for patients.”.

托马西博士说：“我对Entact正在发展的创新模式非常感兴趣，因为它具有巨大的潜力，可以追求被认为对疾病有益的新的、不坚固的目标。”。“公司在开发Enclosure™平台方面取得的进展令人印象深刻，我很高兴能够领导科学工作，分享团队为患者引入新治疗选择的热情。”。

About Entact Bio

关于Entact Bio

Entact Bio is developing a novel class of precision medicines that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitylase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has built its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines.

Entact Bio正在开发一类新型精密药物，可增强有益蛋白质的功能。由一个深深植根于去泛素化酶（DUB）生物化学，化学生物学，疾病生物学和小分子药物开发的创始团队发起，Entact建立了其专有的Encomb™平台，以创建增强靶向嵌合（ENTAC™）药物。

ENTACs leverage the natural ability of DUBs to regulate and enhance protein function. By harnessing the power of DUBs, Entact is expanding the universe of treatable diseases and creating new options for patients who are underserved by current therapeutic modalities. For more information, visit entactbio.com..

ENTAC利用DUB的天然能力来调节和增强蛋白质功能。通过利用DUB的力量，Entact正在扩大可治疗疾病的范围，并为目前治疗方式服务不足的患者创造新的选择。有关更多信息，请访问entactbio.com。。